Association of missense variant DCLRE1B rs3761936 with breast and cervical cancer risk—A case-control study
PLOS One · 2025
DOI: 10.1371/journal.pone.0331492 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift PLOS One, 2025. Verfasst von Sarah Jafrin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Science, Noakhali Science and Technology University, Sonapur, Bangladesh. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Breast Neoplasms, Genetic Predisposition to Disease, Mutation, Missense. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Research Cell, Noakhali Science and Technology University.
Abstract (Originalsprache)
Background
Overexpression of rs3761936 of DCLRE1B gene has been observed in both breast cancer and cervical cancer patients. To justify the association of this polymorphism with these cancers, we performed this case-control study.
Method
A total of 245 cancer patients and 108 healthy controls participated in the research. An efficient T-ARMS PCR method was used for genotyping.
Results
The cancer patients showed higher mutant allele frequency compared to the controls. Mutant allele carrier breast cancer patients showed significantly increased risk in four genetic models, including additive model 1 (TC vs. TT: OR=2.31, 95% CI = 1.33–3.99, p -value = 0.0028), additive model 2 (CC vs. TT: OR=3.93, 95% CI = 1.36–11.38, p -value = 0.0116), dominant model (TC + CC vs. TT: OR=2.52, 95% CI = 1.50–4.25, p -value = 0.0005), and over-dominant model (TC vs. TT + CC: OR=1.93, 95% CI = 1.13–3.28, p -value = 0.0152). The allele frequency analysis showed that mutant allele C carriers among breast cancer patients had a significantly higher risk than the wild type T allele carriers (C vs. T: OR=2.15, 95% CI = 1.41–3.26, p -value = 0.0003). Likewise, the cervical cancer patients showed significant risk in three genetic models, including additive model 1 (TC vs. TT: OR=1.80, 95% CI = 1.01–3.20, p -value = 0.0444), additive model 2 (CC vs. TT: OR=3.17, 95% CI = 1.05–9.55, p -value = 0.0403), and dominant model (TC + CC vs. TT: OR=1.98, 95% CI = 1.15–3.41, p -value = 0.0138). The mutant allele C carriers had a significantly higher risk than the wild-type T allele carriers (C vs. T: OR=1.84, 95% CI = 1.19–2.85, p -value = 0.0065).
Conclusion
DCLRE1B rs3761936 is strongly associated with breast cancer and cervical cancer risk in Bangladeshi women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Science, Noakhali Science and Technology University, Sonapur, Bangladesh.
- Laboratory of Pharmacogenomics and Molecular Biology, Department of Pharmacy, Noakhali Science and Technology University, Noakhali, Bangladesh.
- Bangladesh Pharmacogenomics Research Network (BdPGRN), Noakhali, Bangladesh.
ORCID-Profile: Md Abdul Aziz, Mohammad Safiqul Islam
Förderung
- The Research Cell, Noakhali Science and Technology University
Zitieren
APA
Jafrin, S., Aziz, M. A., Barek, M. A., Reza, M. S., Naznin, N. E., & Islam, M. S. (2025). Association of missense variant DCLRE1B rs3761936 with breast and cervical cancer risk—A case-control study. PLOS One. https://doi.org/10.1371/journal.pone.0331492
Vancouver
Jafrin S, Aziz MA, Barek MA, Reza MS, Naznin NE, Islam MS. Association of missense variant DCLRE1B rs3761936 with breast and cervical cancer risk—A case-control study. PLOS One. 2025. doi:10.1371/journal.pone.0331492
BibTeX
@article{Jafrin2025,
author = {Jafrin, Sarah and Aziz, Md Abdul and Barek, Md Abdul and Reza, Md Sharif and Naznin, Nura Ershad and Islam, Mohammad Safiqul},
title = {Association of missense variant DCLRE1B rs3761936 with breast and cervical cancer risk—A case-control study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0331492}
}
EUVIMED